Princeton-based NJ Bio and Charles River Laboratories on Tuesday announced a strategic alliance to offer complementary services to clients including development and manufacturing of antibody drug conjugates (ADCs).
It is well known that the path of bringing ADCs to market is an intricate and complex field that requires expert navigation skills. It involves development and manufacturing processes of antibodies, cytotoxic payloads, linkers, linker-payloads, their conjugation to ADCs, and preclinical and clinical validations.
The biggest benefit of the Charles River and NJ Bio alliance is that clients can receive seamless complementary services to enhance outcomes and accelerate time-to-market for their ADCs.
Another advantage of this alliance to clients is Charles River’s ability to discover innovative engineered Abs while NJ Bio will synthesize and manufacture novel linkers, payloads, or linker-payloads to enhance the safety and efficacy of ADCs.
Charles River is a leader in antibody development and preclinical evaluation of ADCs.
The Company’s antibody, oncology, immunology and safety assessment experts can support ADC programs from proof-of-concept to clinical candidates, helping drive translational success and accelerating the path to the clinic.
NJ Bio, Inc., is a contract research organization located in Princeton, specializing in providing integrated chemistry and bioconjugation services.
